CRKL

Across TCGA pan-cancer cohorts, CRKL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRKL data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRKL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRKL expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where CRKL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.898	0.642	<.001	48	view →
CCRCC	DFS	Quartile	II,III,IV	0.296	0.722	.003	28	view →
UCEC	OS	Quartile	III,IV	0.296	1.000	.027	20	view →
HNSC	OS	Median	IV	0.610	0.854	.009	20	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRKL–PDAC (DFS)

Open the PDAC breakdown →